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Classical methods for determining malignant disease
prognosis are based upon characterizing the morphology
and location of tumor cells. While this analysis provides
important information about a patient’s disease it fails to
capture the biological complexity of the tumor microen-
vironment and the contribution of the anti-tumor
immune response. Basic histological quantification of T
lymphocyte density, cytotoxicity, and memory by CD3,
CD8, and CD45RO, respectively, has demonstrated that
increased infiltration of T lymphocytes is associated with
statistically significant improvement in patients’ disease-
free survival (DFS) and overall survival (OS) in colorectal
carcinoma (CRC). Delineating the location of T lympho-
cytes into two areas within the primary tumor, the center
and the invading margin is termed Immunoscore.
In this study we examined whether tumor genotype
could predict the clinical outcome of patients with CRC
and if combining Immunoscore with analysis of the tumor
genotype could further enhance the accuracy of predicting
clinical outcome. We analyzed 200 primary colorectal
tumor samples for mutations in 50 common driver genes,
including those implicated in models of colon carcinogen-
esis (APC, KRAS, BRAF, SMAD4). Each mutation was
then assessed for prediction of DFS. Patients presented
with a mean of 4 ± 2 mutations. The most common muta-
tions were in KRAS (58%), TP53 (49%) and APC (37%).
Neither, a single mutation or the number of mutations sig-
nificantly predicted clinical outcome.
We examined whether mutations in the primary tumor
were associated with presence of metastasis. Mutational
profiles were remarkably similar between primary tumors
from patients whether or not they had metastatic progres-
sion at the time of surgery. None of the 50 major cancer
genes was more frequently mutated in patients with
metastasis. However, using integrative analysis we found
that tumors from patients with metastatic disease downre-
gulated adaptive immune genes including those involved
in co-stimulation, proliferation and positive regulation of
T cells. Furthermore when analyzing the ability to predict
patients’ OS using Immunoscore in these late stage
tumors, high Immunoscore still distinguished patients
with better clinical prognosis. These data suggest immune
contexture accurately predicts clinical outcome regardless
of tumor stage. Further analysis of pre-existing immunity
together with the analysis of tumor genotype may provide
better understanding of tumor progression and invasion.
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